Martin James M, Wu Hong, Barta Stefan K
Department of Medicine, Section of Hematology/Oncology, Temple University Hospital, Philadelphia, PA, USA; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Chin Clin Oncol. 2019 Feb;8(1):4. doi: 10.21037/cco.2018.09.06. Epub 2018 Oct 11.
The term "CD30+ T-cell lymphoproliferative disorders" describes a group of diverse diseases of the skin, subcutaneous tissues and mucosa that range from lesions requiring clinical observation to those necessitating systemic cytotoxic chemotherapy. Careful consideration of both clinical and histopathologic presentation is needed for appropriate diagnosis and treatment. This review will present the current classification of these disorders and potential treatment paradigms. Primary cutaneous CD30+ T-cell lymphoproliferative disorders, breast-implant associated anaplastic large-cell lymphoma and mucosal entities will be discussed.
术语“CD30 + T细胞淋巴增殖性疾病”描述了一组皮肤、皮下组织和黏膜的多种疾病，范围从需要临床观察的病变到需要全身细胞毒性化疗的病变。为了进行适当的诊断和治疗，需要仔细考虑临床和组织病理学表现。本综述将介绍这些疾病的当前分类和潜在的治疗模式。将讨论原发性皮肤CD30 + T细胞淋巴增殖性疾病、乳房植入物相关间变性大细胞淋巴瘤和黏膜病变。
